# Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

> **NCT02328014** · PHASE1,PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 40 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma
- Multiple Myeloma
- B-All

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** ACP-319

## Key facts

- **NCT ID:** NCT02328014
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-20
- **Primary completion:** 2020-06-01
- **Final completion:** 2025-10-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-09

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328014, "Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies". Retrieved via AI Analytics 2026-05-18 from https://api.ai-analytics.org/clinical/NCT02328014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*